Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland

References

• Spondylitis Association of AmericaOverview of Ankylosing Spondylitis Available from: https://www.spondylitis.org/Ankylosing-SpondylitisAccessed January 4, 2018
   Google Scholar
• SchettGLoriesRJD’AgostinoMAEnthesitis: from pathophysiology to treatmentNat Rev Rheumatol2017131273174129158573
   PubMed Web of Science ®Google Scholar
• WenkerKJQuintJMAnkylosing SpondylitisTreasure Island (FL)StatPearls Publishing LLC2018
   Google Scholar
• RantalaihoVKautiainenHVirtaLPuolakkaKFRI0560 the increase in the nationwide incidence of inflammatory rheumatic diseases in Finland during this millenniumAnn Rheum Dis201675Suppl 2643644
   Google Scholar
• BoonenAvan der LindenSMThe burden of ankylosing spondylitisJ Rheumatol Suppl20067841117042055
   PubMedGoogle Scholar
• BlanchCComellasMPradaCLizanLEconomic burden of ankylosing spondylitis in Europe. A systematic review of the literatureValue Health2016197A541A542
   Google Scholar
• van der HeijdeDRamiroSLandewéR2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritisAnn Rheum Dis201776697899128087505
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXKiltzUSecukinumab (AIN457) in the treatment of ankylosing spondylitisExpert Opin Biol Ther201616571172226982813
   PubMed Web of Science ®Google Scholar
• Busquets-PerezNMarzo-OrtegaHEmeryPEmerging drugs for axial spondyloarthritis including ankylosing spondylitisExpert Opin Emerg Drugs2013181718623253176
   PubMed Web of Science ®Google Scholar
• PalazziCD’AngeloSGilioMLeccesePPadulaAOlivieriIPharmacological therapy of spondyloarthritisExpert Opin Pharmacother201516101495150426073668
   PubMed Web of Science ®Google Scholar
• The Social Insurance Institution of FinlandSpecial reimbursement (281) Available from: https://www.kela.fi/laake281Accessed April 24, 2018
   Google Scholar
• DougadosMBaetenDSpondyloarthritisLancet201137797832127213721684383
   PubMed Web of Science ®Google Scholar
• NOVARTISNovartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis 2015 Available from: https://www.myscience.org/news/wire/novartis_receives_two_landmark_european_approvals_for_cosen-tyx_treat_patients_with_ankylosing_spond-2015-novartisAccessed January 31, 2019
   Google Scholar
• BraunJBaraliakosXDeodharAEffect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III measure 1 studyAnn Rheum Dis20177661070107727965257
   PubMed Web of Science ®Google Scholar
• SieperJDeodharAMarzo-OrtegaHSecukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the measure 2 studyAnn Rheum Dis201776357159227582421
   PubMed Web of Science ®Google Scholar
• Marzo-OrtegaHSieperJKivitzASecukinumab and sustained improvement in signs and symptoms of patients with active ankylosing spondylitis through two years: results from a phase III studyArthritis Care Res (Hoboken)20176971020102928235249
   PubMed Web of Science ®Google Scholar
• DeodharAABaetenDSieperJPorterBRichardsHWidmerASafety and tolerability of secukinumab in patients with active anky-losing spondylitis: pooled safety analysis of two phase 3, randomized, controlled trialsArthritis Rheum20156734783479
   Google Scholar
• MaksymowychWPStrandVNashPComparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison: an analysis based on all pivotal phase 3 clinical trial dataArthritis Rheum201668Suppl 10
   Google Scholar
• LeeYHSongGGComparative efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis: a Bayesian network meta-analysis of randomized controlled trialsJ Rheum Dis2017244211219
   Google Scholar
• European Medicines Agency Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyxAccessed January 31, 2019
   Google Scholar
• CorbettMSoaresMJhutiGTumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluationHealth Technol Assess20162091334
   PubMed Web of Science ®Google Scholar
• BaetenDMeasePStrandVSAT0390 secukinumab for the treatment of ankylosing spondylitis: comparative effectiveness results versus currently licensed biologics from a network meta-analysisAnn Rheum Dis201675Suppl 2809.280810
   Google Scholar
• EderLChandranVShenHCookRJGladmanDDIs ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?Ann Rheum Dis201069122160216420627946
   PubMedGoogle Scholar
• KeatABarkhamNBhallaABSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working Party of the British Society for RheumatologyRheumatology (Oxford)200544793994715901904
   PubMedGoogle Scholar
• NICEGolimumab for the treatment of ankylosing spondylitisNICE Technology Appraisal 2332011 Available from: https://www.nice.org.uk/guidance/ta233Accessed July 2017
   Google Scholar
• NICETNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: NICE technology appraisal2016 Available from: https://www.nice.org.uk/guidance/TA383Accessed July 2017
   Google Scholar
• Kustannus Oy DuodecimMedicinal products and prices database Available from: https://www.duodecim.fi/duodecim/Accessed February 1, 2018
   Google Scholar
• CorbettMSoaresMJhuntiGTNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233)CRD/CHE Technology Assessment Group (Centre for Review and Dissemination/Centre for Health Economics) University of York122014 Available from: https://www.nice.org.uk/guidance/ta383/documents/ankylosing-spondylitis-and-axial-spondylo-arthritis-nonradiographic-adalimumab-etanercept-infliximab-and-golim-umab-inc-rev-ta143-and-ta233-id694-appraisal-consultation-document2Accessed February 7, 2018
   Google Scholar
• BaklandGGranJTNossentJCIncreased mortality in ankylosing spondylitis is related to disease activityAnn Rheum Dis201170111921192521784726
   PubMed Web of Science ®Google Scholar
• AbuabaraKAzfarRSShinDBNeimannALTroxelABGelfandJMCause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UKBr J Dermatol2010163358659220633008
   PubMed Web of Science ®Google Scholar
• Statistics FinlandRisk of dying during a year by age and sex (year 2015) Available from: http://www.stat.fi/index_en.htmlAccessed August 15, 2017
   Google Scholar
• Garrido-CastroJLMedina-CarnicerRSchiottisRGalisteoAMCollantes-EstevezEGonzalez-NavasCAssessment of spinal mobility in ankylosing spondylitis using a video-based motion capture systemMan Ther201217542242622560166
   PubMedGoogle Scholar
• McLeodCBagustABolandAAdalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluationHealth Technol Assess200711281158iiiiv
   Web of Science ®Google Scholar
• GoereeRChiva-RazaviSGundaPJainMJuglSMCost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspectiveJ Med Econ2019221455230346844
   PubMed Web of Science ®Google Scholar
• Marzo-OrtegaHHallidayAJuglSThe cost-effectiveness of secukinumab versus tumour necrosis factor α inhibitor biosimilars FOR ankylosing spondylitis in the UKRheumatology201756suppl_2kex062.108
   Google Scholar
• EmeryPvan KeepMBeardSCost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UKPharmacoeconomics20183681015102729797186
   PubMed Web of Science ®Google Scholar
• SariozFOzdemirODirekSCavusoglu SezenSBarutcugilMSecukinumab is dominant vs. TNF-inhibitors in the treatment of active ankylosing spondylitis: results from a Turkish cost-effectiveness modelValue Health2017209A534
   Google Scholar
• Romero PradaMERoa CardenasNCSerranoGYHuerfanoLMCostutility analysis of secukinumab use versus TNF-α inhibitors, in patients with ankylosing spondilytisValue Health2017209A938A939
   Google Scholar
• DjambazovSVekovTIncremental cost-effectiveness analysis of biological drug therapies for the treatment of ankylosing spondylitis in Bulgaria, 2016ISPOR 22nd Annual International MeetingMay 2017Boston, MA, USA
   Google Scholar
• FedyaevDDerkachEVCost-effectiveness analysis of different biologic agents for ankylosing spondylitis treatment in RussiaValue Health2016197A539
   Google Scholar
• BaraliakosXKivitzAJDeodharAALong-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the phase 3 measure 1 trialClin Exp Rheumatol20183615055
   PubMed Web of Science ®Google Scholar
• HaglundEBremanderABergmanSJacobssonLTPeterssonIFWork productivity in a population-based cohort of patients with spondyloarthritisRheumatology (Oxford)20135291708171423804223
   PubMed Web of Science ®Google Scholar
• RamondaRMarchesoniACarlettoAPatient-reported impact of spondyloarthritis on work disability and working life: the Atlantis surveyArthritis Res Ther20161817827037139
   PubMed Web of Science ®Google Scholar
• de HoogeMRamondaRLorenzinMWork productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the space cohortArthritis Res Ther201618126527852321
   PubMedGoogle Scholar
• EdwardsCJFautrelBSchulze-KoopsHHuizingaTWJKrugerKDosing down with biologic therapies: a systematic review and clinicians’ perspectiveRheumatology (Oxford)201756111847185628339632
   PubMed Web of Science ®Google Scholar
• LorenzinMOrtolanAde HoogeMLengthening the time intervals between doses of biological agents in psoriatic arthritis patients: a single-center retrospective studyInt J Immunopathol Pharmacol201528447948726384393
   PubMed Web of Science ®Google Scholar
• ArendsSvan der VeerEKampsFBPatient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practiceClin Exp Rheumatol201533217418025797228
   PubMedGoogle Scholar
• ZávadaJUherMSisolKA tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort studyAnn Rheum Dis20167519610225165033
   PubMedGoogle Scholar
• De StefanoRFratiEde QuattroDMenzaLManganelliSLow doses of etanercept can be effective to maintain remission in ankylosing spondylitis patientsClin Rhfeumatol2014335707711
   PubMedGoogle Scholar
• RamiroSStolwijkCvan TubergenAEvolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS studyAnn Rheum Dis2015741525923956249
   PubMedGoogle Scholar
• SoiniEJLeussuMHallinenTAdministration costs of intravenous biologic drugs for rheumatoid arthritisSpringerplus20132153124255834
   PubMedGoogle Scholar